Catherine Moukheibir - Jun 6, 2024 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Stock symbol
MLTX
Transactions as of
Jun 6, 2024
Transactions value $
$0
Form type
4
Date filed
6/7/2024, 05:01 PM
Previous filing
Dec 19, 2023
Next filing
Jun 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Award $0 +7.69K $0.00 7.69K Jun 6, 2024 Class A ordinary shares, par value $0.0001 per share 7.69K $42.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.